Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination
Author:
Publisher
Elsevier BV
Subject
Transplantation,Surgery
Reference28 articles.
1. Strategies to improve long-term outcomes after renal transplantation;Pascual;N Engl J Med,2002
2. Transplant: immunology and treatment of rejection;Davis;Am J Kidney Dis,2004
3. Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican) [Editorial];Monaco;Transplantation,2005
4. Banff 07 classification of renal allograft pathology: update and future directions;Solez;Am J Transplant,2008
5. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies;Olyaei;Curr Opin Crit Care,2001
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers after Renal Transplantation;Journal of Clinical Medicine;2020-01-23
2. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy;American Journal of Transplantation;2018-06-03
3. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial;Nephrology Dialysis Transplantation;2017-06-01
4. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis;American Journal of Transplantation;2016-03-15
5. Safety of mTOR inhibitors in adult solid organ transplantation;Expert Opinion on Drug Safety;2016-01-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3